OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study

Reuters11-25

<a href="https://laohu8.com/S/OSRH">OSR Holdings</a> Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study

OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the performance of the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck system in both mouse-type and stick-type models against a standard laboratory reference device. The findings, based on a Clinical Study Report completed in 2023, demonstrated that the system achieved accuracy and reliability comparable to leading commercially available minimally invasive continuous glucose monitors. The results have already been presented by the company. Building on this data, Woori IO and Samsung are conducting a new proof-of-concept study, and a formal MFDS-compliant clinical trial is planned for the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586397444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586397444","market":"nz","top_or_hot":-1,"title":"OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSRH\">OSR Holdings</a> Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the performance of the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck system in both mouse-type and stick-type models against a standard laboratory reference device. The findings, based on a Clinical Study Report completed in 2023, demonstrated that the system achieved accuracy and reliability comparable to leading commercially available minimally invasive continuous glucose monitors. The results have already been presented by the company. Building on this data, Woori IO and Samsung are conducting a new proof-of-concept study, and a formal MFDS-compliant clinical trial is planned for the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSRH\">OSR Holdings</a> Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the performance of the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck system in both mouse-type and stick-type models against a standard laboratory reference device. The findings, based on a Clinical Study Report completed in 2023, demonstrated that the system achieved accuracy and reliability comparable to leading commercially available minimally invasive continuous glucose monitors. The results have already been presented by the company. Building on this data, Woori IO and Samsung are conducting a new proof-of-concept study, and a formal MFDS-compliant clinical trial is planned for the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSRH","symbol_name":"OSR Holdings","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL8b9YH3:1","article_id":"2586397444","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586397444","pubTimestamp":1764053007,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the performance of the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck system in both mouse-type and stick-type models against a standard laboratory reference device. The findings, based on a Clinical Study Report completed in 2023, demonstrated that the system achieved accuracy and reliability comparable to leading commercially available minimally invasive continuous glucose monitors. The results have already been presented by the company. Building on this data, Woori IO and Samsung are conducting a new proof-of-concept study, and a formal MFDS-compliant clinical trial is planned for the first half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OSRH":"OSR Holdings","BK4139":"生物科技"},"translate_title":"OSR Holdings报告Woori IO无创血糖监测仪在试点研究中具有高准确性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSRH":0.9},"content_text":"OSR Holdings Reports High Accuracy for Woori IO Noninvasive Glucose Monitor in Pilot Study\n    \n\n        OSR Holdings Inc. has announced the results of a company-sponsored pilot study evaluating the performance of the Glucheck noninvasive blood glucose measurement system, developed by its subsidiary Woori IO in collaboration with Korea University Guro Hospital. The study, conducted from May 9 to September 12, 2023, assessed the accuracy, stability, and usability of the Glucheck system in both mouse-type and stick-type models against a standard laboratory reference device. The findings, based on a Clinical Study Report completed in 2023, demonstrated that the system achieved accuracy and reliability comparable to leading commercially available minimally invasive continuous glucose monitors. The results have already been presented by the company. Building on this data, Woori IO and Samsung are conducting a new proof-of-concept study, and a formal MFDS-compliant clinical trial is planned for the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586397444","isCrawlerRequest":true}